This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Value Investors Pick Gilead Sciences (GILD) Stock?
by Zacks Equity Research
Is Gilead Sciences (GILD) a great pick from the value investor's perspective right now? Read on to know more.
Unity (UBX) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
Unity (UBX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Gilead Inks Gene Editing Collaboration Deal for HBV Infection
by Zacks Equity Research
Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.
Company News For Sep 13, 2018
by Zacks Equity Research
Companies in the news are: GILD, VZ, BHC and WBC
Gilead's Rheumatoid Arthritis Drug Successful in Phase III
by Zacks Equity Research
Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secondary endpoints in first phase III study.
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
by Zacks Equity Research
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
Merck's Antibacterial Drug Succeeds in Label Expansion Study
by Zacks Equity Research
Merck's (MRK) label expansion study evaluating its antibacterial drug, Zerbaxa for two types of pneumonia infections meets primary endpoints.
Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA
by Zacks Equity Research
The FDA will review Regeneron (REGN) and Sanofi's sBLA for its PCSK9 Inhibitor Praluent to reduce risk of major adverse cardiovascular events.
Incyte, Foundation Medicine Partner for Companion Diagnostics
by Zacks Equity Research
Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
Endocyte Announces FDA's Acceptance of Trial Endpoint Change
by Zacks Equity Research
177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $72.51, moving +0.36% from the previous trading session.
Shire's ADHD Portfolio Remains Strong Amid Competition
by Zacks Equity Research
Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
by Zacks Equity Research
Inovio (INO) focuses on the development of its most advanced candidate, VGX-3100 vaccine, which has been progressing well. Its collaboration with big pharma companies exhibits strong growth.
The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE
Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine
by Zacks Equity Research
Inovio Pharmaceuticals (INO) administers dosage in the first patient under a phase I/IIa trial to assess its MERS vaccine INO-4700.
Top Research Reports for Abbott, Gilead & FedEx
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Gilead (GILD) and FedEx (FDX).
bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy
by Zacks Equity Research
bluebird bio (BLUE) announces updated results from phase II/III Starbeam study of its Lenti-D gene therapy in boys aged 17 years or below with CALD.
Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint
by Zacks Equity Research
Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.
ProQR Up More Than 120% on Favorable Eye Disorder Study Data
by Zacks Equity Research
ProQR Therapeutics (PRQR) presents positive data from a phase I/II study on QR-110, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx
by Zacks Equity Research
Puma Biotech (PBYI) gains EU approval for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
Horizon Pharma Completes Enrollment in Eye Disease Study
by Zacks Equity Research
Horizon Pharma (HZNP) completes early enrollment for the confirmatory phase III study of teprotumumab, which is being evaluated for the treatment of thyroid eye disease.
Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout
by Zacks Equity Research
Bayer (BAYRY) misses earnings estimates in the second quarter of 2018. The company completes the acquisition of Monsanto for $63 billion.
MannKind Stock Up on Licensing Deal With United Therapeutics
by Zacks Equity Research
MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.
Alnylam's Shares Up as Onpattro Gets FDA and EU Approvals
by Zacks Equity Research
Shares of Alnylam (ALNY) increase due to the FDA and European approval for Onpattro.
Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)
by Zacks Equity Research
Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.